3.4 · Therapeutic index, interactions and placebo reasoning

Learning objective

Interpret population safety indices and distinguish pharmacokinetic interactions, pharmacodynamic interactions and contextual effects.

Population response is different from response magnitude

A quantal curve counts the fraction of a population reaching a defined endpoint. ED50 is the dose producing that endpoint in 50% of the studied population; it is not automatically a dose producing half of each person’s maximal response. In the book’s animal example, therapeutic index is LD50/ED50. A toxicity endpoint can instead use TD50/ED50. The endpoint, species and conditions must be stated. A ratio summarizes separation between population curves, not a guaranteed safe dose for an individual.

Distinguish window from index

A therapeutic window is a concentration or exposure range used for a particular drug and effect context. A therapeutic index is a ratio derived from specified population endpoints. People vary in absorption, metabolism, organ function, targets and context. A single average or median does not describe every individual.

Two interaction mechanisms

A pharmacokinetic interaction changes another drug’s absorption, distribution, metabolism or excretion, and therefore its exposure. A pharmacodynamic interaction changes the combined response at targets or systems even without changing concentrations. Polypharmacy means use of multiple medications; the label alone does not establish that a combination is helpful or harmful. Identify the mechanism and measured outcome.

Expectation and study design

Placebo effects concern treatment context and expectation; nocebo effects concern adverse responses associated with negative expectations. Improvement in a placebo group can also include natural change and measurement effects, so it is not all a pure expectation effect. Randomization, masking and appropriate comparison groups help interpret drug-specific effects. Supplementary FDA phase terminology: phase 1 emphasizes safety and dosage, phase 2 explores efficacy and side effects, phase 3 tests benefit and monitors adverse reactions in larger groups, and phase 4 occurs after approval.

Check your understanding

Explain it without notes

How could two drugs increase a shared effect without changing either concentration?

Why does improvement after a treatment not by itself establish a specific drug effect?

Revisit the connected course lessons and visuals

Therapeutic window, steady state and washout

Biopsychosocial context and differences

Primary and secondary effects

Julien’s Primer of Drug Action, supplied consolidated PDF pages 39, 40, 41 (Chapter 3). Locators refer to PDF captures, not printed pages. Original paraphrase and practice; source conformance reviewed, not independently clinically certified. Professor or supplementary clarifications are identified in the lesson and source list.